HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/ml

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 56-59

  Mitsuya, Yumi ^a   Winters, Mark A ^a   Fessel, W Jeffrey ^b   Rhee, Soo Yon ^a   Slome, Sally ^b   Flamm, Jason ^b   Horberg, Michael ^b   Hurley, Leo ^b   Klein, Daniel ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Genotypic testing; Low viral load; Population based sequencing

Indexed keywords

RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RNA ANALYSIS; VALIDATION PROCESS; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHYLOGENY; RNA, VIRAL; VIRAL LOAD;

EID: 33748096590     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000232609.99705.a2     Document Type: Article

References (13)

1. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
2. de Mendoza C, Soriano V, Perez-Olmeda M, et al. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol. 1999;2:344-349.
3. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15:2379-2384.
4. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-1969.
5. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003;17:1741-1751.
6. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis. 2003;37:113-128.
7. Yeni PG, Hammer SM, Hirsch MS, Saag MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251-265.
8. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV A Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (The living document, October 6, 2005). Available at: http://aidsinfo.nih.gov/. Accessed February 12, 2006.
9. Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 2004;119:73-78.
10. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml. AIDS. 2006;20:778-779.
11. Shafer RW, Hertogs K, Zolopa AR, et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol. 2001;39:1522-1529.
12. Gonzales MJ, Dugan JM, Shafer RW. Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN). Bioinformatics. 2002;18:886-887.
13. Shafer RW, Levee DJ, Winters MA, et al. Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol. 1997;35:520-522.